Who is sponsoring NCT03616483?

NCT03616483 is sponsored by Indiana University.

What drugs are being tested in NCT03616483?

Interventions in NCT03616483: This is a non-interventional trial.

What condition does NCT03616483 study?

NCT03616483 studies Plasma Cell Dyscrasias.

Is NCT03616483 still recruiting?

NCT03616483 is currently recruiting now. Last updated 10 November 2025.

Last reviewed 2025-11-10 · How we verify

NCT03616483

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Indiana Myeloma Registry

Recruiting now Last updated 10 November 2025

What this trial tests

trial testing This is a non-interventional trial in Plasma Cell Dyscrasias in 2,500 participants. Currently enrolling.

Timeline

18 June 2018

Primary endpoint
30 June 2028

30 June 2028

Quick facts

Lead sponsor	Indiana University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	2,500
Start date	18 June 2018
Primary completion	30 June 2028
Estimated completion	30 June 2028
Sites	1 location across United States

Drugs / interventions tested

This is a non-interventional trial

Conditions studied

Plasma Cell Dyscrasias — all drugs for Plasma Cell Dyscrasias →

Sponsor

Indiana University

Who can join

18 and older, any sex, with Plasma Cell Dyscrasias. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cryopreservation Preserves Cell-Type Composition and Gene Expression Profiles in Bone Marrow Aspirates From Multiple Myeloma Patients.
Chen D, Abu Zaid MI, Reiter JL, Czader M, et al · · 2021 · cited 22× · PMID 33968139 · DOI 10.3389/fgene.2021.663487
Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups.
Liu E, Jaouadi O, Sharma R, Becker N, et al · · 2025 · cited 2× · PMID 40665393 · DOI 10.1186/s13073-025-01503-y

Verify or expand the search:

Other Indiana University trials

Trials by the same sponsor.

NCT07470086 — The Role of Environmental Temperatures in Respiratory Control · NA · not yet recruiting
NCT07470099 — The Role of Breathing Perception in Respiratory Control · NA · not yet recruiting
NCT07179952 — Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) · Phase 2 · not yet recruiting
NCT07070804 — Maternal Biomarkers and Environmental Contributors to Autism Spectrum Disorders in Children of First-time Mothers · not yet recruiting
NCT07499583 — Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03616483 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Indiana University
Last refreshed: 10 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03616483.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing